196 related articles for article (PubMed ID: 8826929)
1. Morphologic and molecular cytogenetics in neuroblastoma.
Avet-Loiseau H; Venuat AM; Benard J; Leibovitch MP; Hartmann O; Bernheim A
Cancer; 1995 Apr; 75(7):1694-9. PubMed ID: 8826929
[TBL] [Abstract][Full Text] [Related]
2. Correlation between the number of segmental chromosome aberrations and the age at diagnosis of diploid neuroblastomas without MYCN amplification.
Souzaki R; Tajiri T; Teshiba R; Kinoshita Y; Yosue R; Kohashi K; Oda Y; Taguchi T
J Pediatr Surg; 2011 Dec; 46(12):2228-32. PubMed ID: 22152855
[TBL] [Abstract][Full Text] [Related]
3. Detection of MYCN gene amplification and deletions of chromosome 1p in neuroblastoma by in situ hybridization using routine histologic sections.
Leong PK; Thorner P; Yeger H; Ng K; Zhang Z; Squire J
Lab Invest; 1993 Jul; 69(1):43-50. PubMed ID: 8331897
[TBL] [Abstract][Full Text] [Related]
4. Neuroblastoma--clinical applications of molecular parameters.
Brodeur GM
Brain Pathol; 1990 Sep; 1(1):47-54. PubMed ID: 1669693
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma.
Tanaka S; Tajiri T; Noguchi S; Shono K; Ihara K; Hara T; Suita S
J Pediatr Surg; 2004 Jan; 39(1):63-8. PubMed ID: 14694373
[TBL] [Abstract][Full Text] [Related]
6. Application of fluorescence in situ hybridization to detect N-myc (MYCN) gene amplification on paraffin-embedded tissue sections of neuroblastomas.
Hachitanda Y; Saito M; Mori T; Hamazaki M
Med Pediatr Oncol; 1997 Aug; 29(2):135-8. PubMed ID: 9180916
[TBL] [Abstract][Full Text] [Related]
7. Fluorescence in situ hybridization (FISH) detection of MYCN oncogene amplification in neuroblastoma using paraffin-embedded tissues.
Misra DN; Dickman PS; Yunis EJ
Diagn Mol Pathol; 1995 Jun; 4(2):128-35. PubMed ID: 7551293
[TBL] [Abstract][Full Text] [Related]
8. The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.
Bogen D; Brunner C; Walder D; Ziegler A; Abbasi R; Ladenstein RL; Noguera R; Martinsson T; Amann G; Schilling FH; Ussowicz M; Benesch M; Ambros PF; Ambros IM
Int J Cancer; 2016 Jul; 139(1):153-63. PubMed ID: 26910568
[TBL] [Abstract][Full Text] [Related]
9. MYCN amplification and 17q in neuroblastoma: evidence for structural association.
O'Neill S; Ekstrom L; Lastowska M; Roberts P; Brodeur GM; Kees UR; Schwab M; Bown N
Genes Chromosomes Cancer; 2001 Jan; 30(1):87-90. PubMed ID: 11107180
[TBL] [Abstract][Full Text] [Related]
10. 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group.
Bown N; Lastowska M; Cotterill S; O'Neill S; Ellershaw C; Roberts P; Lewis I; Pearson AD;
Med Pediatr Oncol; 2001 Jan; 36(1):14-9. PubMed ID: 11464868
[TBL] [Abstract][Full Text] [Related]
11. Rapid and accurate determination of MYCN copy number and 1p deletion in neuroblastoma by quantitative PCR.
Anderson J; Gibson S; Williamson D; Rampling D; Austin C; Shipley J; Sebire N; Brock P
Pediatr Blood Cancer; 2006 Jun; 46(7):820-4. PubMed ID: 16220551
[TBL] [Abstract][Full Text] [Related]
12. 8q deletion in MYCN-amplified neuroblastoma of a child born from assisted reproductive technology.
Brassesco MS; Valera ET; de Oliveira FM; de Paula Queiroz RG; Scrideli CA; Sakamoto-Hojo ET; Tone LG
J Pediatr Hematol Oncol; 2009 Mar; 31(3):215-9. PubMed ID: 19262252
[TBL] [Abstract][Full Text] [Related]
13. Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients. U.K. Children's Cancer Study Group and the U.K. Cancer Cytogenetics Group.
Lastowska M; Cotterill S; Pearson AD; Roberts P; McGuckin A; Lewis I; Bown N
Eur J Cancer; 1997 Sep; 33(10):1627-33. PubMed ID: 9389925
[TBL] [Abstract][Full Text] [Related]
14. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.
Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL
Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009
[TBL] [Abstract][Full Text] [Related]
15. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B
J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128
[TBL] [Abstract][Full Text] [Related]
16. Investigation of MYCN status in neuroblastoma by fluorescence in situ hybridization.
Wan TS; Ma ES; Chan GC; Chan LC
Int J Mol Med; 2004 Dec; 14(6):981-7. PubMed ID: 15547663
[TBL] [Abstract][Full Text] [Related]
17. In vivo elimination of acentric double minutes containing amplified MYCN from neuroblastoma tumor cells through the formation of micronuclei.
Valent A; BĂ©nard J; Clausse B; Barrois M; Valteau-Couanet D; Terrier-Lacombe MJ; Spengler B; Bernheim A
Am J Pathol; 2001 May; 158(5):1579-84. PubMed ID: 11337354
[TBL] [Abstract][Full Text] [Related]
18. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
[TBL] [Abstract][Full Text] [Related]
19. Fluorescence in situ hybridization analysis of chromosome 1p36 deletions in human MYCN amplified neuroblastoma.
Komuro H; Valentine MB; Rowe ST; Kidd VJ; Makino S; Brodeur GM; Cohn SL; Look AT
J Pediatr Surg; 1998 Nov; 33(11):1695-8. PubMed ID: 9856898
[TBL] [Abstract][Full Text] [Related]
20. Evolution of unbalanced gain of distal chromosome 2p in neuroblastoma.
Stallings RL; Carty P; McArdle L; Mullarkey M; McDermott M; O'Meara A; Ryan E; Catchpoole D; Breatnach F
Cytogenet Genome Res; 2004; 106(1):49-54. PubMed ID: 15218241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]